U.S. Markets open in 3 hrs 23 mins

WTX101: A Superior Treatment for Wilson Disease

Sarah Collins
WTX101: A Superior Treatment for Wilson Disease

On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced the acquisition of Wilson Therapeutics, which is developing a “first-of-its-kind” treatment for Wilson disease. Currently, Wilson disease is treated with copper chelators, Penicillamine or Trientine, to remove copper from serum. The drug has the potential to become the standard of care for Wilson disease patients.